Terminated PHASE2 INTERVENTIONAL 2-arm NCT00267007

A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 18 Week Pilot Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) on the Development of Peripheral Neuropathy in Patients Receiving Combination Taxane and Platinum-Based Chemotherapy for Cancer

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Conditions Peripheral Neuropathy, Chemotherapy-induced

Interventions PROCRIT 40,000 IU QW Placebo

Updated 8 times since 2017 Last updated: May 21, 2014 Started: Jun 30, 2006 Primary completion: Aug 31, 2008 Completion: Aug 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow enrollment

Other terminated trials from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

More terminations from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

A PHASE2 clinical study on Peripheral Neuropathy, Chemotherapy-induced, this trial is terminated or withdrawn. The trial is conducted by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and has accumulated 8 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Ortho Biotech Clinical Affairs, L.L.C.

Data source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alhambra, United States , Augusta, United States , Bakersfield, United States , Bethesda, United States , Buffalo, United States , Chattanooga, United States , Detroit, United States , Durham, United States , Fullerton, United States , Hollywood, United States and 18 more locations